Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 14/20 | 0.60 |
| ▸ | JAK1 | P23458 | 12/20 | 0.60 |
| ▸ | EGFR | P00533 | 5/20 | 0.60 |
| ▸ | BTK | Q06187 | 4/20 | 0.60 |
| ▸ | SYK | P43405 | 4/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.60 |
| ▸ | CDK1 | P06493 | 3/20 | 0.60 |
| ▸ | CDK2 | P24941 | 3/20 | 0.60 |
| ▸ | JAK2 | O60674 | 3/20 | 0.60 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.60 |
| ▸ | AURKA | O14965 | 2/20 | 0.60 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.60 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.60 |
| ▸ | PRKCG | P05129 | 2/20 | 0.60 |
| ▸ | LCK | P06239 | 2/20 | 0.60 |
| ▸ | FYN | P06241 | 2/20 | 0.60 |
| ▸ | LYN | P07948 | 2/20 | 0.60 |
| ▸ | RET | P07949 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2473715 | 0.94 | JAK3 (0.64) | JAK3JAK1EGFRBTKSYK | |
| SCHEMBL2474786 | 0.94 | JAK3 (0.56) | JAK3JAK1EGFRBTKSYK | |
| SCHEMBL2472009 | 0.90 | NTRK1 (0.67) | JAK3JAK1EGFRBTKSYK | |
| SCHEMBL2474363 | 0.90 | NTRK1 (0.59) | JAK3JAK1EGFRBTKSYK | |
| SCHEMBL2474134 | 0.90 | EGFR (0.52) | JAK3JAK1EGFRBTKSYK | |
| SCHEMBL17685307 | 0.88 | JAK3 (0.59) | JAK3JAK1EGFRBTKSYK | |
| SCHEMBL4971374 | 0.86 | JAK3 (0.62) | JAK3JAK1EGFRBTKSYK | |
| SCHEMBL4971164 | 0.85 | JAK3 (0.65) | JAK3JAK1EGFRBTKSYK | |
| SCHEMBL1605709 | 0.84 | EGFR (0.52) | JAK3JAK1EGFRBTKSYK | |
| SCHEMBL1606288 | 0.84 | EGFR (0.52) | JAK3JAK1EGFRBTKSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370415-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2016-04-20 | — | — | EP | claimed |
| US-8268851-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | claimed |
| EP-2370415-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Rigel Pharmaceuticals, Inc. (US) | 2011-10-05 | — | — | EP | claimed |
| WO-2010075558-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | WO | claimed |
| US-20100158921-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | US | claimed |
| EP-2370415-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-8420659-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120301486-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Riger Pharmaceuticals, Inc. | 2012-11-29 | — | — | US | disclosed |
| US-8268851-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100158921-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158921-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885EGFR 529/4885 |
| US-20120301486-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK3 1/4885JAK1 3/4885EGFR 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.